Trial Profile

A phase 3 study assessing ATH434

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 13 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Feb 2025 According to an Alterity Therapeutics media release, company announced that it has received binding commitments for a capital raising of A$40.0 million via a two tranche placement to Australian and international institutions and other unrelated sophisticated, professional or exempt investors. Funds to be used primarily to advance development of ATH434 .
26 Mar 2024 According to an Alterity Therapeutics media release, company has received A$3.9 million cash refund from the Australian Taxation Office under the Australian Government's Research and Development Tax Incentive (R&DTI) Scheme. These funds will be used to further Alterity's clinical trials in MSA (planned Phase 3 clinical trial in MSA).
13 Mar 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com